Management of buried penis syndrome: The novel therapeutic DJ- SAM (Deepak Jumani-Sesame Arginine Metformin) approach

Despite all advances in the treatment of patients with multiple myeloma, relapse is a constant event in this disease. Novel therapeutic agents like proteasome inhibitors, immunomodulatory drugs and their combinations have improved overall survival in patients with relapsed or refractory myeloma, with partial remission achieved in 50-70% and median duration of 6-14 months, as well as the quality of life of these patients. The novel therapeutic agents presented known and acceptable safety profile. The choice of the appropriate regimen is depending on components of initial therapy, degree of response and remission duration, patient?s status like age, performance status, renal function impairment, pre-existing medical toxicity, cytogenetic abnormalities and, at the other side, aggressiveness of relapsed disease.

Download Full-text

The New Paradigms in Clinical Research: From Early Access Programs to the Novel Therapeutic Approaches for Unmet Medical Needs

Frontiers in Pharmacology ◽

10.3389/fphar.2019.00111 ◽

2019 ◽

Vol 10 ◽

Cited By ~ 12

Author(s):

Cristina Scavone ◽

Gabriella di Mauro ◽

Annamaria Mascolo ◽

Liberato Berrino ◽

Francesco Rossi ◽

...

Keyword(s):

Clinical Research ◽

The Novel ◽

Therapeutic Approaches ◽

Medical Needs ◽

Early Access ◽

Unmet Medical Needs ◽

Novel Therapeutic ◽

Access Programs

Download Full-text

Development of Immunopathogenesis Strategies to Treat Behçet’s Disease

Pathology Research International ◽

10.1155/2012/261989 ◽

2012 ◽

Vol 2012 ◽

pp. 1-7 ◽

Cited By ~ 4

Author(s):

Osman Köse

Keyword(s):

Molecular Structure ◽

Biologic Agents ◽

Treatment Modalities ◽

The Novel ◽

Therapeutic Modalities ◽

Novel Treatment ◽

Unclear Etiology ◽

Antigen Presenting ◽

Disease Understanding ◽

Novel Therapeutic

Behçet disease is a chronic relapsing vasculitis with unclear etiology and immunopathogenesis. Antigenic stimuli, antigen presenting cells, T cells, monocyte, and neutrophil and endothelial cells are major parts of the pathology of the disease. Understanding of the new pathogenic mechanisms based on molecular structure of the disease helps us in improving the novel therapeutic modalities. These drugs target specific and nonspecific inhibition of the immun system. These therapies include biologic agents, new topical and systemic immunosuppressants, tolerizing agents, and immunoablation. Novel treatment will be promising to treat the especially recalcitrant cases to conventional therapy. In this paper, new aspect of the immunopathogenesis of Behçet’s diseases and novel treatment modalities will be discussed.

Download Full-text

Abstract 1597: Inhibition of the novel therapeutic target pregnancy associated plasma protein A (PAPP-A) in Ewing sarcoma enhances efficacy of IGF1R targeting in vivo

10.1158/1538-7445.am2017-1597 ◽

2017 ◽

Author(s):

Sabine Heitzeneder ◽

John F. Shern ◽

Lee J. Helman ◽

Javed Khan ◽

Crystal L. Mackall

Keyword(s):

Plasma Protein ◽

Ewing Sarcoma ◽

Therapeutic Target ◽

Protein A ◽

The Novel ◽

Novel Therapeutic

Download Full-text

Not all hematopoietic growth factors are created equal: should we gain information for their use with immunotherapy?

Journal for ImmunoTherapy of Cancer ◽

10.1136/jitc-2021-003154 ◽

2021 ◽

Vol 9 (8) ◽

pp. e003154

Author(s):

Paolo Bossi ◽

Cristina Gurizzan ◽

Luigi Lorini ◽

Pierluigi di Mauro ◽

Chiara Sardini ◽

...

Keyword(s):

Growth Factors ◽

The Novel ◽

Granulocyte Colony Stimulating Factor ◽

Negative Consequences ◽

Colony Stimulating Factor ◽

Hematopoietic Growth Factors ◽

Chemotherapy Induced Neutropenia ◽

Stimulating Factor ◽

Therapeutic Administration ◽

Novel Therapeutic

Myeloid growth factors, either granulocyte colony-stimulating factor (CSF) or granulocyte-macrophage CSF, are widely used to reduce the incidence and severity of chemotherapy-induced neutropenia by prophylactic or therapeutic administration. However, their activity in the novel therapeutic regimens, which often rely on the association between immunotherapy and chemotherapy, has not been thoroughly characterized yet. This paper presents some of the preclinical and clinical research regarding the putative interplay between myeloid growth factors and the immune system, advocating further studies to elucidate their potential positive or negative consequences on the outcomes when administered with immunotherapeutic agents.

Download Full-text